Analyst Gil Blum of Needham maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report), retaining the price target of $6.00.
Gil Blum has given his Buy rating due to a combination of factors surrounding Taysha Gene Therapies’ promising developments. The completion of dosing in the REVEAL studies without any new safety concerns is a positive indicator, suggesting that the TSHA-102 treatment is progressing well. The anticipation of deeper effects over time for Rett syndrome patients further supports this optimistic outlook.
Additionally, the upcoming clinical updates scheduled for the first half of 2025, which will provide results from both high and low dose patients, are expected to offer valuable insights. These updates will allow for a more comprehensive comparison with competitors like Neurogene’s NGN-401. Moreover, Taysha’s financial position, with $139 million in funds, ensures operational stability into the fourth quarter of 2026, which is a reassuring factor for investors.
According to TipRanks, Blum is an analyst with an average return of -9.7% and a 32.80% success rate. Blum covers the Healthcare sector, focusing on stocks such as Geron, Sarepta Therapeutics, and Cartesian Therapeutics.